المؤلفون: Alba-Arbalat, Salut, Solana, Elisabeth, Lopez-Soley, Elisabet, Camos-Carreras, Anna, Martinez-Heras, Eloy, Vivó, Francesc, Pulido-Valdeolivas, Irene, Andorra, Magi, Sepulveda, Maria, Cabrera, Jose María, Fonseca, Elianet, Calvi, Alberto, Alcubierre, Rafel, Dotti-Boada, Marina, Saiz, Albert, Martinez-Lapiscina, Elena H, Villoslada, Pablo, Blanco, Yolanda, Sanchez-Dalmau, Bernardo, Llufriu, Sara

مصطلحات موضوعية: Multiple sclerosis

الوصف: Background We investigated the association between changes in retinal thickness and cognition in people with MS (PwMS), exploring the predictive value of optical coherence tomography (OCT) markers of neuroaxonal damage for global cognitive decline at different periods of disease. Method We quantified the peripapillary retinal nerve fibre (pRFNL) and ganglion cell-inner plexiform (GCIPL) layers thicknesses of 207 PwMS and performed neuropsychological evaluations. The cohort was divided based on disease duration (≤5 years or >5 years). We studied associations between changes in OCT and cognition over time, and assessed the risk of cognitive decline of a pRFNL≤88 µm or GCIPL≤77 µm and its predictive value. Results Changes in pRFNL and GCIPL thickness over 3.2 years were associated with evolution of cognitive scores, in the entire cohort and in patients with more than 5 years of disease (p<0.01). Changes in cognition were related to less use of disease-modifying drugs, but not OCT metrics in PwMS within 5 years of onset. A pRFNL≤88 µm was associated with earlier cognitive disability (3.7 vs 9.9 years) and higher risk of cognitive deterioration (HR=1.64, p=0.022). A GCIPL≤77 µm was not associated with a higher risk of cognitive decline, but a trend was observed at ≤91.5 µm in PwMS with longer disease (HR=1.81, p=0.061). Conclusions The progressive retinal thinning is related to cognitive decline, indicating that cognitive dysfunction is a late manifestation of accumulated neuroaxonal damage. Quantifying the pRFNL aids in identifying individuals at risk of cognitive dysfunction.

وصف الملف: text/html

العلاقة: http://jnnp.bmj.com/cgi/content/short/95/5/419Test; http://dx.doi.org/10.1136/jnnp-2023-332332Test

الإتاحة: https://doi.org/10.1136/jnnp-2023-332332Test
http://jnnp.bmj.com/cgi/content/short/95/5/419Test

المؤلفون: Kennedy, Keith E., Kerlero de Rosbo, Nicole, Uccelli, Antonio, Cellerino, Maria, Ivaldi, Federico, Contini, Paola, De Palma, Raffaele, Harbo, Hanne F., Berge, Tone, Bos, Steffan D., Høgestøl, Einar A., Brune-Ingebretsen, Synne, de Rodez Benavent, Sigrid A., Paul, Friedemann, Brandt, Alexander U., Bäcker-Koduah, Priscilla, Behrens, Janina, Kuchling, Joseph, Asseyer, Susanna, Scheel, Michael, Chien, Claudia, Zimmermann, Hanna, Motamedi, Seyedamirhosein, Kauer-Bonin, Josef, Saez-Rodriguez, Julio, Rinas, Melanie, Alexopoulos, Leonidas G., Andorra, Magi, Llufriu, Sara, Saiz, Albert, Blanco, Yolanda, Martinez-Heras, Eloy, Solana, Elisabeth, Pulido-Valdeolivas, Irene, Martinez-Lapiscina, Elena H., Garcia-Ojalvo, Jordi, Villoslada, Pablo

المساهمون: Zhang, Zhaolei, Horizon 2020 Framework Programme, Instituto de Salud Carlos III, Ministero della Salute, Deutsches Teilprojekt B, Norwegian Research Council

المصدر: PLOS Computational Biology ; volume 20, issue 2, page e1010980 ; ISSN 1553-7358

الوصف: Complex diseases such as Multiple Sclerosis (MS) cover a wide range of biological scales, from genes and proteins to cells and tissues, up to the full organism. In fact, any phenotype for an organism is dictated by the interplay among these scales. We conducted a multilayer network analysis and deep phenotyping with multi-omics data (genomics, phosphoproteomics and cytomics), brain and retinal imaging, and clinical data, obtained from a multicenter prospective cohort of 328 patients and 90 healthy controls. Multilayer networks were constructed using mutual information for topological analysis, and Boolean simulations were constructed using Pearson correlation to identified paths within and among all layers. The path more commonly found from the Boolean simulations connects protein MK03, with total T cells, the thickness of the retinal nerve fiber layer (RNFL), and the walking speed. This path contains nodes involved in protein phosphorylation, glial cell differentiation, and regulation of stress-activated MAPK cascade, among others. Specific paths identified were subsequently analyzed by flow cytometry at the single-cell level. Combinations of several proteins (GSK3AB, HSBP1 or RS6) and immune cells (Th17, Th1 non-classic, CD8, CD8 Treg, CD56 neg, and B memory) were part of the paths explaining the clinical phenotype. The advantage of the path identified from the Boolean simulations is that it connects information about these known biological pathways with the layers at higher scales (retina damage and disability). Overall, the identified paths provide a means to connect the molecular aspects of MS with the overall phenotype.

الإتاحة: https://doi.org/10.1371/journal.pcbi.1010980Test

المؤلفون: Asseyer, Susanna, Asgari, Nasrin, Bennett, Jeffrey, Bialer, Omer, Blanco, Yolanda, Bosello, Francesca, Camos-Carreras, Anna, Carnero Contentti, Edgar, Carta, Sara, Chen, John, Chien, Claudia, Chomba, Mashina, Dale, Russell C, Dalmau, Josep, Feldmann, Kristina, Flanagan, Eoin P, Froment Tilikete, Caroline, Garcia-Alfonso, Carolina, Havla, Joachim, Hellmann, Mark, Kim, Ho Jin, Klyscz, Philipp, Konietschke, Frank, La Morgia, Chiara, Lana-Peixoto, Marco, Leite, Maria Isabel, Levin, Netta, Levy, Michael, Llufriu, Sara, Lopez, Pablo, Lotan, Itay, Lugaresi, Alessandra, Marignier, Romain, Mariotto, Sara, Mollan, Susan P, Ocampo, Cassandra, Cosima Oertel, Frederike, Olszewska, Maja, Palace, Jacqueline, Pandit, Lekha, Peralta Uribe, José Luis, Pittock, Sean, Ramanathan, Sudarshini, Rattanathamsakul, Natthapon, Saiz, Albert, Samadzadeh, Sara, Sanchez-Dalmau, Bernardo, Saylor, Deanna, Scheel, Michael, Schmitz-Hübsch, Tanja, Shifa, Jemal, Siritho, Sasitorn, Sperber, Pia S, Subramanian, Prem S, Tiosano, Alon, Vaknin-Dembinsky, Adi, Mejia Vergara, Alvaro Jose, Wilf-Yarkoni, Adi, Zarco, Luis Alfonso, Zimmermann, Hanna G, Paul, Friedemann, Stiebel-Kalish, Hadas

المساهمون: Asseyer, Susanna, Asgari, Nasrin, Bennett, Jeffrey, Bialer, Omer, Blanco, Yolanda, Bosello, Francesca, Camos-Carreras, Anna, Carnero Contentti, Edgar, Carta, Sara, Chen, John, Chien, Claudia, Chomba, Mashina, Dale, Russell C, Dalmau, Josep, Feldmann, Kristina, Flanagan, Eoin P, Froment Tilikete, Caroline, Garcia-Alfonso, Carolina, Havla, Joachim, Hellmann, Mark, Kim, Ho Jin, Klyscz, Philipp, Konietschke, Frank, La Morgia, Chiara, Lana-Peixoto, Marco, Leite, Maria Isabel, Levin, Netta, Levy, Michael, Llufriu, Sara, Lopez, Pablo, Lotan, Itay, Lugaresi, Alessandra, Marignier, Romain, Mariotto, Sara, Mollan, Susan P, Ocampo, Cassandra, Cosima Oertel, Frederike, Olszewska, Maja, Palace, Jacqueline, Pandit, Lekha, Peralta Uribe, José Lui, Pittock, Sean, Ramanathan, Sudarshini, Rattanathamsakul, Natthapon, Saiz, Albert, Samadzadeh, Sara, Sanchez-Dalmau, Bernardo, Saylor, Deanna, Scheel, Michael, Schmitz-Hübsch, Tanja, Shifa, Jemal, Siritho, Sasitorn, Sperber, Pia S, Subramanian, Prem S, Tiosano, Alon, Vaknin-Dembinsky, Adi, Mejia Vergara, Alvaro Jose, Wilf-Yarkoni, Adi, Zarco, Luis Alfonso, Zimmermann, Hanna G, Paul, Friedemann, Stiebel-Kalish, Hadas

مصطلحات موضوعية: Aquaporin-4-IgG (AQP4-IgG), MOG-IgG associated disorders (MOGAD), clinically isolated syndrome (CIS), multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), optic neuritis (ON)

الوصف: Optic neuritis (ON) often occurs at the presentation of multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD). The recommended treatment of high-dose corticosteroids for ON is based on a North American study population, which did not address treatment timing or antibody serostatus. The Acute Optic Neuritis Network (ACON) presents a global, prospective, observational study protocol primarily designed to investigate the effect of time to high-dose corticosteroid treatment on 6-month visual outcomes in ON. Patients presenting within 30 days of the inaugural ON will be enrolled. For the primary analysis, patients will subsequently be assigned into the MS-ON group, the aquapotin-4-IgG positive ON (AQP4-IgG+ON) group or the MOG-IgG positive ON (MOG-IgG+ON) group and then further sub-stratified according to the number of days from the onset of visual loss to high-dose corticosteroids (days-to-Rx). The primary outcome measure will be high-contrast best-corrected visual acuity (HC-BCVA) at 6 months. In addition, multimodal data will be collected in subjects with any ON (CIS-ON, MS-ON, AQP4-IgG+ON or MOG-IgG+ON, and seronegative non-MS-ON), excluding infectious and granulomatous ON. Secondary outcomes include low-contrast best-corrected visual acuity (LC-BCVA), optical coherence tomography (OCT), magnetic resonance imaging (MRI) measurements, serum and cerebrospinal fluid (CSF) biomarkers (AQP4-IgG and MOG-IgG levels, neurofilament, and glial fibrillary protein), and patient reported outcome measures (headache, visual function in daily routine, depression, and quality of life questionnaires) at presentation at 6-month and 12-month follow-up visits. Data will be collected from 28 academic hospitals from Africa, Asia, the Middle East, Europe, North America, South America, and Australia. Planned recruitment consists of 100 MS-ON, 50 AQP4-IgG+ON, and 50 MOG-IgG+ON. This prospective, multimodal data collection will assess the ...

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36908609; info:eu-repo/semantics/altIdentifier/wos/WOS:000982373000001; volume:14; issue:1102353; firstpage:1; lastpage:16; numberofpages:16; journal:FRONTIERS IN NEUROLOGY; https://hdl.handle.net/11562/1088208Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85150165727; https://doi.org/10.3389/fneur.2023.1102353Test

الإتاحة: https://doi.org/10.3389/fneur.2023.1102353Test
https://hdl.handle.net/11562/1088208Test

المؤلفون: Martinez-Heras, Eloy, Solana, Elisabeth, Vivó, Francesc, Lopez-Soley, Elisabet, Calvi, Alberto, Alba-Arbalat, Salut, Schoonheim, Menno M, Strijbis, Eva M, Vrenken, Hugo, Barkhof, Frederik, Rocca, Maria A, Filippi, Massimo, Pagani, Elisabetta, Groppa, Sergiu, Fleischer, Vinzenz, Dineen, Robert A, Bellenberg, Barbara, Lukas, Carsten, Pareto, Deborah, Rovira, Alex, Sastre-Garriga, Jaume, Collorone, Sara, Prados, Ferran, Toosy, Ahmed, Ciccarelli, Olga, Saiz, Albert, Blanco, Yolanda, Llufriu, Sara

المساهمون: Martinez-Heras, Eloy, Solana, Elisabeth, Vivó, Francesc, Lopez-Soley, Elisabet, Calvi, Alberto, Alba-Arbalat, Salut, Schoonheim, Menno M, Strijbis, Eva M, Vrenken, Hugo, Barkhof, Frederik, Rocca, Maria A, Filippi, Massimo, Pagani, Elisabetta, Groppa, Sergiu, Fleischer, Vinzenz, Dineen, Robert A, Bellenberg, Barbara, Lukas, Carsten, Pareto, Deborah, Rovira, Alex, Sastre-Garriga, Jaume, Collorone, Sara, Prados, Ferran, Toosy, Ahmed, Ciccarelli, Olga, Saiz, Albert, Blanco, Yolanda, Llufriu, Sara

مصطلحات موضوعية: MULTIPLE SCLEROSIS, NEUROIMMUNOLOGY

الوصف: Background: We aimed to describe the severity of the changes in brain diffusion-based connectivity as multiple sclerosis (MS) progresses and the microstructural characteristics of these networks that are associated with distinct MS phenotypes. Methods: Clinical information and brain MRIs were collected from 221 healthy individuals and 823 people with MS at 8 MAGNIMS centres. The patients were divided into four clinical phenotypes: clinically isolated syndrome, relapsing-remitting, secondary progressive and primary progressive. Advanced tractography methods were used to obtain connectivity matrices. Then, differences in whole-brain and nodal graph-derived measures, and in the fractional anisotropy of connections between groups were analysed. Support vector machine algorithms were used to classify groups. Results: Clinically isolated syndrome and relapsing-remitting patients shared similar network changes relative to controls. However, most global and local network properties differed in secondary progressive patients compared with the other groups, with lower fractional anisotropy in most connections. Primary progressive participants had fewer differences in global and local graph measures compared with clinically isolated syndrome and relapsing-remitting patients, and reductions in fractional anisotropy were only evident for a few connections. The accuracy of support vector machine to discriminate patients from healthy controls based on connection was 81%, and ranged between 64% and 74% in distinguishing among the clinical phenotypes. Conclusions: In conclusion, brain connectivity is disrupted in MS and has differential patterns according to the phenotype. Secondary progressive is associated with more widespread changes in connectivity. Additionally, classification tasks can distinguish between MS types, with subcortical connections being the most important factor.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37321841; info:eu-repo/semantics/altIdentifier/wos/WOS:001010973500001; journal:JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY; https://hdl.handle.net/20.500.11768/144556Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85164481874; https://jnnp.bmj.com/content/early/2023/06/14/jnnp-2023-331531Test

الإتاحة: https://doi.org/20.500.11768/144556Test
https://doi.org/10.1136/jnnp-2023-331531Test
https://hdl.handle.net/20.500.11768/144556Test
https://jnnp.bmj.com/content/early/2023/06/14/jnnp-2023-331531Test

المؤلفون: Asseyer, Susanna, Asgari, Nasrin, Bennett, Jeffrey, Bialer, Omer, Blanco, Yolanda, Bosello, Francesca, Camos-Carreras, Anna, Carnero Contentti, Edgar, Carta, Sara, Chen, John, Chien, Claudia, Chomba, Mashina, Dale, Russell C., Dalmau, Josep, Feldmann, Kristina, Flanagan, Eoin P., Froment Tilikete, Caroline, Garcia-Alfonso, Carolina, Havla, Joachim, Hellmann, Mark, Kim, Ho Jin, Klyscz, Philipp, Konietschke, Frank, La Morgia, Chiara, Lana-Peixoto, Marco, Leite, Maria Isabel, Levin, Netta, Levy, Michael, Llufriu, Sara, Lopez, Pablo, Lotan, Itay, Lugaresi, Alessandra, Marignier, Romain, Mariotto, Sara, Mollan, Susan P., Ocampo, Cassandra, Cosima Oertel, Frederike, Olszewska, Maja, Palace, Jacqueline, Pandit, Lekha, Peralta Uribe, José Luis, Pittock, Sean, Ramanathan, Sudarshini, Rattanathamsakul, Natthapon, Saiz, Albert, Samadzadeh, Sara, Sanchez-Dalmau, Bernardo, Saylor, Deanna, Scheel, Michael, Schmitz-Hübsch, Tanja, Shifa, Jemal, Siritho, Sasitorn, Sperber, Pia S., Subramanian, Prem S., Tiosano, Alon, Vaknin-Dembinsky, Adi, Mejia Vergara, Alvaro Jose, Wilf-Yarkoni, Adi, Zarco, Luis Alfonso, Zimmermann, Hanna G., Paul, Friedemann, Stiebel-Kalish, Hadas

المساهمون: Asseyer, Susanna, Asgari, Nasrin, Bennett, Jeffrey, Bialer, Omer, Blanco, Yolanda, Bosello, Francesca, Camos-Carreras, Anna, Carnero Contentti, Edgar, Carta, Sara, Chen, John, Chien, Claudia, Chomba, Mashina, Dale, Russell C., Dalmau, Josep, Feldmann, Kristina, Flanagan, Eoin P., Froment Tilikete, Caroline, Garcia-Alfonso, Carolina, Havla, Joachim, Hellmann, Mark, Kim, Ho Jin, Klyscz, Philipp, Konietschke, Frank, La Morgia, Chiara, Lana-Peixoto, Marco, Leite, Maria Isabel, Levin, Netta, Levy, Michael, Llufriu, Sara, Lopez, Pablo, Lotan, Itay, Lugaresi, Alessandra, Marignier, Romain, Mariotto, Sara, Mollan, Susan P., Ocampo, Cassandra, Cosima Oertel, Frederike, Olszewska, Maja, Palace, Jacqueline, Pandit, Lekha, Peralta Uribe, José Lui, Pittock, Sean, Ramanathan, Sudarshini, Rattanathamsakul, Natthapon, Saiz, Albert, Samadzadeh, Sara, Sanchez-Dalmau, Bernardo, Saylor, Deanna, Scheel, Michael, Schmitz-Hübsch, Tanja, Shifa, Jemal, Siritho, Sasitorn, Sperber, Pia S., Subramanian, Prem S., Tiosano, Alon, Vaknin-Dembinsky, Adi, Mejia Vergara, Alvaro Jose, Wilf-Yarkoni, Adi, Zarco, Luis Alfonso, Zimmermann, Hanna G., Paul, Friedemann, Stiebel-Kalish, Hadas

مصطلحات موضوعية: optic neuritis, treatment, prognosis, MOG, aquaporin-4

الوصف: Optic neuritis (ON) often occurs at the presentation of multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD). The recommended treatment of high-dose corticosteroids for ON is based on a North American study population, which did not address treatment timing or antibody serostatus. The AcuteOpticNeuritis Network (ACON) presents a global, prospective, observational study protocol primarily designed to investigate the effect of time to high-dose corticosteroid treatment on 6-month visual outcomes in ON. Patients presenting within 30 days of the inaugural ON will be enrolled. For the primary analysis, patients will subsequently be assigned into the MS-ON group, the aquaporin-4-IgG positive ON (AQP4-IgG+ON) group or the MOG-IgG positive ON (MOG- IgG+ON) group and then further sub-stratified according to the number of days from the onset of visual loss to high-dose corticosteroids (days-to-Rx). The primary outcome measure will be high-contrast best-corrected visual acuity (HC-BCVA) at 6 months. In addition, multimodal data will be collected in subjects with any ON (CIS-ON, MS-ON, AQP4-IgG+ON or MOG-IgG+ON, and seronegative non-MS-ON), excluding infectious and granulomatous ON. Secondary outcomes include low-contrast best-corrected visual acuity (LC-BCVA), optical coherence tomography (OCT), magnetic resonance imaging (MRI) measurements, serum and cerebrospinal fluid (CSF) biomarkers (AQP4-IgG and MOG-IgG levels, neurofilament, and glial fibrillary protein), and patient reported outcome measures (headache, visual function in daily routine, depression, and quality of life questionnaires) at presentation at 6-month and 12-month follow-up visits. Data will be collected from 28 academic hospitals from Africa, Asia, the Middle East, Europe, North America, South America, and Australia. Planned recruitment consists of 100 MS-ON, 50 AQP4-IgG+ON, and 50 MOG-IgG+ON. This prospective, multimodal data collection will assess the ...

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36908609; info:eu-repo/semantics/altIdentifier/wos/WOS:000982373000001; volume:14; firstpage:1; lastpage:16; numberofpages:16; journal:FRONTIERS IN NEUROLOGY; https://hdl.handle.net/11585/919942Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85150165727; https://www.frontiersin.org/articles/10.3389/fneur.2023.1102353/fullTest

الإتاحة: https://doi.org/10.3389/fneur.2023.1102353Test
https://hdl.handle.net/11585/919942Test

المؤلفون: Asseyer, Susanna, Asgari, Nasrin, Bennett, Jeffrey, Bialer, Omer, Blanco, Yolanda, Bosello, Francesca, Camos-Carreras, Anna, Carnero Contentti, Edgar, Carta, Sara, Chen, John, Chien, Claudia, Chomba, Mashina, Dale, Russell, Dalmau, Josep, Feldmann, Kristina, Flanagan, Eoin, Froment Tilikete, Caroline, Garcia-Alfonso, Carolina, Havla, Joachim, Hellmann, Mark, Kim, Ho Jin, Klyscz, Philipp, Konietschke, Frank, La Morgia, Chiara, Lana-Peixoto, Marco, Leite, Maria Isabel, Levin, Netta, Levy, Michael, Llufriu, Sara, Lopez, Pablo, Lotan, Itay, Lugaresi, Alessandra, Marignier, Romain, Mariotto, Sara, Mollan, Susan, Ocampo, Cassandra, Cosima Oertel, Frederike, Olszewska, Maja, Palace, Jacqueline, Pandit, Lekha, Peralta Uribe, José Luis, Pittock, Sean, Ramanathan, Sudarshini, Rattanathamsakul, Natthapon, Saiz, Albert, Samadzadeh, Sara, Sanchez-Dalmau, Bernardo, Saylor, Deanna, Scheel, Michael, Schmitz-Hübsch, Tanja, Shifa, Jemal, Siritho, Sasitorn, Sperber, Pia, Subramanian, Prem, Tiosano, Alon, Vaknin-Dembinsky, Adi, Mejia Vergara, Alvaro Jose, Wilf-Yarkoni, Adi, Zarco, Luis Alfonso, Zimmermann, Hanna, Paul, Friedemann, Stiebel-Kalish, Hadas

المساهمون: Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

المصدر: ISSN: 1664-2295 ; Frontiers in Neurology ; https://hal.science/hal-04316068Test ; Frontiers in Neurology, 2023, 14, pp.1102353. ⟨10.3389/fneur.2023.1102353⟩.

مصطلحات موضوعية: Aquaporin-4-IgG (AQP4-IgG), clinically isolated syndrome (CIS), MOG-IgG associated disorders (MOGAD), multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), optic neuritis (ON), [SCCO.NEUR]Cognitive science/Neuroscience, [SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organs, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie

الوصف: Optic neuritis (ON) often occurs at the presentation of multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD). The recommended treatment of high-dose corticosteroids for ON is based on a North American study population, which did not address treatment timing or antibody serostatus. The Acute Optic Neuritis Network (ACON) presents a global, prospective, observational study protocol primarily designed to investigate the effect of time to high-dose corticosteroid treatment on 6-month visual outcomes in ON. Patients presenting within 30 days of the inaugural ON will be enrolled. For the primary analysis, patients will subsequently be assigned into the MS-ON group, the aquapotin-4-IgG positive ON (AQP4-IgG+ON) group or the MOG-IgG positive ON (MOG-IgG+ON) group and then further sub-stratified according to the number of days from the onset of visual loss to high-dose corticosteroids ( days-to-Rx ). The primary outcome measure will be high-contrast best-corrected visual acuity (HC-BCVA) at 6 months. In addition, multimodal data will be collected in subjects with any ON (CIS-ON, MS-ON, AQP4-IgG+ON or MOG-IgG+ON, and seronegative non-MS-ON), excluding infectious and granulomatous ON. Secondary outcomes include low-contrast best-corrected visual acuity (LC-BCVA), optical coherence tomography (OCT), magnetic resonance imaging (MRI) measurements, serum and cerebrospinal fluid (CSF) biomarkers (AQP4-IgG and MOG-IgG levels, neurofilament, and glial fibrillary protein), and patient reported outcome measures (headache, visual function in daily routine, depression, and quality of life questionnaires) at presentation at 6-month and 12-month follow-up visits. Data will be collected from 28 academic hospitals from Africa, Asia, the Middle East, Europe, North America, South America, and Australia. Planned recruitment consists of 100 MS-ON, 50 AQP4-IgG+ON, and 50 MOG-IgG+ON. This prospective, multimodal data collection will assess ...

العلاقة: hal-04316068; https://hal.science/hal-04316068Test; https://hal.science/hal-04316068/documentTest; https://hal.science/hal-04316068/file/fneur-14-1102353.pdfTest

الإتاحة: https://doi.org/10.3389/fneur.2023.1102353Test
https://hal.science/hal-04316068Test
https://hal.science/hal-04316068/documentTest
https://hal.science/hal-04316068/file/fneur-14-1102353.pdfTest

المؤلفون: Martinez-Heras, Eloy, Solana, Elisabeth, Vivó, Francesc, Lopez-Soley, Elisabet, Calvi, Alberto, Alba-Arbalat, Salut, Schoonheim, Menno M, Strijbis, Eva M, Vrenken, Hugo, Barkhof, Frederik, Rocca, Maria A, Filippi, Massimo, Pagani, Elisabetta, Groppa, Sergiu, Fleischer, Vincenz, Dineen, Robert A, Ballenberg, Barbara, Lukas, Carsten, Pareto, Deborah, Rovira, Alex, Sastre-Garriga, Jaume, Collorone, Sara, Prados, Ferran, Toosy, Ahmed, Ciccarelli, Olga, Saiz, Albert, Blanco, Yolanda, Llufriu, Sara

الوصف: Background: We aimed to describe the severity of the changes in brain diffusion-based connectivity as multiple sclerosis (MS) progresses and the microstructural characteristics of these networks that are associated with distinct MS phenotypes.Methods: Clinical information and brain MRIs were collected from 221 healthy individuals and 823 people with MS at 8 MAGNIMS centres. The patients were divided into four clinical phenotypes: clinically isolated syndrome, relapsing-remitting, secondary progressive and primary progressive. Advanced tractography methods were used to obtain connectivity matrices. Then, differences in whole-brain and nodal graph-derived measures, and in the fractional anisotropy of connections between groups were analysed. Support vector machine algorithms were used to classify groups.Results: Clinically isolated syndrome and relapsing-remitting patients shared similar network changes relative to controls. However, most global and local network properties differed in secondary progressive patients compared with the other groups, with lower fractional anisotropy in most connections. Primary progressive participants had fewer differences in global and local graph measures compared with clinically isolated syndrome and relapsing-remitting patients, and reductions in fractional anisotropy were only evident for a few connections. The accuracy of support vector machine to discriminate patients from healthy controls based on connection was 81%, and ranged between 64% and 74% in distinguishing among the clinical phenotypes.Conclusions: In conclusion, brain connectivity is disrupted in MS and has differential patterns according to the phenotype. Secondary progressive is associated with more widespread changes in connectivity. Additionally, classification tasks can distinguish between MS types, with subcortical connections being the most important factor.

العلاقة: https://nottingham-repository.worktribe.com/output/19010097Test; Journal of Neurology, Neurosurgery and Psychiatry; Volume 94; Issue 11; Pagination 916-923; https://nottingham-repository.worktribe.com/file/19010097/1/Lui_AAMTest

الإتاحة: https://doi.org/10.1136/jnnp-2023-331531Test
https://nottingham-repository.worktribe.com/file/19010097/1/Lui_AAMTest
https://nottingham-repository.worktribe.com/output/19010097Test

المؤلفون: Asseyer, Susanna, Asgari, Nasrin, Bennett, Jeffrey, Bialer, Omer, Blanco, Yolanda, Bosello, Francesca, Camos-Carreras, Anna, Carnero Contentti, Edgar, Carta, Sara, Chen, John, Chien, Claudia, Chomba, Mashina, Dale, Russell, Dalmau, Josep, Feldmann, Kristina, Flanagan, Eoin, Froment Tilikete, Caroline, Garcia-Alfonso, Carolina, Havla, Joachim, Hellmann, Mark, Kim, Ho Jin, Klyscz, Philipp, Konietschke, Frank, La Morgia, Chiara, Lana-Peixoto, Marco, Leite, Maria Isabel, Levin, Netta, Levy, Michael, Llufriu, Sara, Lopez, Pablo, Lotan, Itay, Lugaresi, Alessandra, Marignier, Romain, Mariotto, Sara, Mollan, Susan, Ocampo, Cassandra, Cosima Oertel, Frederike, Olszewska, Maja, Palace, Jacqueline, Pandit, Lekha, Peralta Uribe, José Luis, Pittock, Sean, Ramanathan, Sudarshini, Rattanathamsakul, Natthapon, Saiz, Albert, Samadzadeh, Sara, Sanchez-Dalmau, Bernardo, Saylor, Deanna, Scheel, Michael, Schmitz-Hübsch, Tanja, Shifa, Jemal, Siritho, Sasitorn, Sperber, Pia, Subramanian, Prem, Tiosano, Alon, Vaknin-Dembinsky, Adi, Mejia Vergara, Alvaro Jose, Wilf-Yarkoni, Adi, Zarco, Luis Alfonso, Zimmermann, Hanna, Paul, Friedemann, Stiebel-Kalish, Hadas

المساهمون: Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

المصدر: ISSN: 1664-2295 ; Frontiers in Neurology ; https://hal.science/hal-04316068Test ; Frontiers in Neurology, 2023, 14, pp.1102353. ⟨10.3389/fneur.2023.1102353⟩.

مصطلحات موضوعية: Aquaporin-4-IgG (AQP4-IgG), clinically isolated syndrome (CIS), MOG-IgG associated disorders (MOGAD), multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), optic neuritis (ON), [SCCO.NEUR]Cognitive science/Neuroscience, [SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organs, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie

الوصف: Optic neuritis (ON) often occurs at the presentation of multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD). The recommended treatment of high-dose corticosteroids for ON is based on a North American study population, which did not address treatment timing or antibody serostatus. The Acute Optic Neuritis Network (ACON) presents a global, prospective, observational study protocol primarily designed to investigate the effect of time to high-dose corticosteroid treatment on 6-month visual outcomes in ON. Patients presenting within 30 days of the inaugural ON will be enrolled. For the primary analysis, patients will subsequently be assigned into the MS-ON group, the aquapotin-4-IgG positive ON (AQP4-IgG+ON) group or the MOG-IgG positive ON (MOG-IgG+ON) group and then further sub-stratified according to the number of days from the onset of visual loss to high-dose corticosteroids ( days-to-Rx ). The primary outcome measure will be high-contrast best-corrected visual acuity (HC-BCVA) at 6 months. In addition, multimodal data will be collected in subjects with any ON (CIS-ON, MS-ON, AQP4-IgG+ON or MOG-IgG+ON, and seronegative non-MS-ON), excluding infectious and granulomatous ON. Secondary outcomes include low-contrast best-corrected visual acuity (LC-BCVA), optical coherence tomography (OCT), magnetic resonance imaging (MRI) measurements, serum and cerebrospinal fluid (CSF) biomarkers (AQP4-IgG and MOG-IgG levels, neurofilament, and glial fibrillary protein), and patient reported outcome measures (headache, visual function in daily routine, depression, and quality of life questionnaires) at presentation at 6-month and 12-month follow-up visits. Data will be collected from 28 academic hospitals from Africa, Asia, the Middle East, Europe, North America, South America, and Australia. Planned recruitment consists of 100 MS-ON, 50 AQP4-IgG+ON, and 50 MOG-IgG+ON. This prospective, multimodal data collection will assess ...

العلاقة: hal-04316068; https://hal.science/hal-04316068Test; https://hal.science/hal-04316068/documentTest; https://hal.science/hal-04316068/file/fneur-14-1102353.pdfTest

الإتاحة: https://doi.org/10.3389/fneur.2023.1102353Test
https://hal.science/hal-04316068Test
https://hal.science/hal-04316068/documentTest
https://hal.science/hal-04316068/file/fneur-14-1102353.pdfTest

المؤلفون: Asseyer, Susanna, Asgari, Nasrin, Bennett, Jeffrey, Bialer, Omer, Blanco, Yolanda, Bosello, Francesca, Camos-Carreras, Anna, Carnero Contentti, Edgar, Carta, Sara, Chen, John, Chien, Claudia, Chomba, Mashina, Dale, Russell, Dalmau, Josep, Feldmann, Kristina, Flanagan, Eoin, Froment Tilikete, Caroline, Garcia-Alfonso, Carolina, Havla, Joachim, Hellmann, Mark, Kim, Ho Jin, Klyscz, Philipp, Konietschke, Frank, La Morgia, Chiara, Lana-Peixoto, Marco, Leite, Maria Isabel, Levin, Netta, Levy, Michael, Llufriu, Sara, Lopez, Pablo, Lotan, Itay, Lugaresi, Alessandra, Marignier, Romain, Mariotto, Sara, Mollan, Susan, Ocampo, Cassandra, Cosima Oertel, Frederike, Olszewska, Maja, Palace, Jacqueline, Pandit, Lekha, Peralta Uribe, José Luis, Pittock, Sean, Ramanathan, Sudarshini, Rattanathamsakul, Natthapon, Saiz, Albert, Samadzadeh, Sara, Sanchez-Dalmau, Bernardo, Saylor, Deanna, Scheel, Michael, Schmitz-Hübsch, Tanja, Shifa, Jemal, Siritho, Sasitorn, Sperber, Pia, Subramanian, Prem, Tiosano, Alon, Vaknin-Dembinsky, Adi, Mejia Vergara, Alvaro Jose, Wilf-Yarkoni, Adi, Zarco, Luis Alfonso, Zimmermann, Hanna, Paul, Friedemann, Stiebel-Kalish, Hadas

المساهمون: Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

المصدر: ISSN: 1664-2295 ; Frontiers in Neurology ; https://hal.science/hal-04316068Test ; Frontiers in Neurology, 2023, 14, pp.1102353. ⟨10.3389/fneur.2023.1102353⟩.

مصطلحات موضوعية: Aquaporin-4-IgG (AQP4-IgG), clinically isolated syndrome (CIS), MOG-IgG associated disorders (MOGAD), multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), optic neuritis (ON), [SCCO.NEUR]Cognitive science/Neuroscience, [SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organs, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie

الوصف: Optic neuritis (ON) often occurs at the presentation of multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD). The recommended treatment of high-dose corticosteroids for ON is based on a North American study population, which did not address treatment timing or antibody serostatus. The Acute Optic Neuritis Network (ACON) presents a global, prospective, observational study protocol primarily designed to investigate the effect of time to high-dose corticosteroid treatment on 6-month visual outcomes in ON. Patients presenting within 30 days of the inaugural ON will be enrolled. For the primary analysis, patients will subsequently be assigned into the MS-ON group, the aquapotin-4-IgG positive ON (AQP4-IgG+ON) group or the MOG-IgG positive ON (MOG-IgG+ON) group and then further sub-stratified according to the number of days from the onset of visual loss to high-dose corticosteroids ( days-to-Rx ). The primary outcome measure will be high-contrast best-corrected visual acuity (HC-BCVA) at 6 months. In addition, multimodal data will be collected in subjects with any ON (CIS-ON, MS-ON, AQP4-IgG+ON or MOG-IgG+ON, and seronegative non-MS-ON), excluding infectious and granulomatous ON. Secondary outcomes include low-contrast best-corrected visual acuity (LC-BCVA), optical coherence tomography (OCT), magnetic resonance imaging (MRI) measurements, serum and cerebrospinal fluid (CSF) biomarkers (AQP4-IgG and MOG-IgG levels, neurofilament, and glial fibrillary protein), and patient reported outcome measures (headache, visual function in daily routine, depression, and quality of life questionnaires) at presentation at 6-month and 12-month follow-up visits. Data will be collected from 28 academic hospitals from Africa, Asia, the Middle East, Europe, North America, South America, and Australia. Planned recruitment consists of 100 MS-ON, 50 AQP4-IgG+ON, and 50 MOG-IgG+ON. This prospective, multimodal data collection will assess ...

العلاقة: hal-04316068; https://hal.science/hal-04316068Test; https://hal.science/hal-04316068/documentTest; https://hal.science/hal-04316068/file/fneur-14-1102353.pdfTest

الإتاحة: https://doi.org/10.3389/fneur.2023.1102353Test
https://hal.science/hal-04316068Test
https://hal.science/hal-04316068/documentTest
https://hal.science/hal-04316068/file/fneur-14-1102353.pdfTest

المؤلفون: Roos, Izanne, Hughes, Stella, McDonnell, Gavin, Malpas, Charles B., Sharmin, Sifat, Boz, Cavit, Alroughani, Raed, Ozakbas, Serkan, Buzzard, Katherine, Skibina, Olga, van der Walt, Anneke, Butzkueven, Helmut, Lechner-Scott, Jeannette, Kuhle, Jens, Terzi, Murat, Laureys, Guy, Van Hijfte, Liesbeth, John, Nevin, Grammond, Pierre, Grand’Maison, Francois, Soysal, Aysun, Jensen, Ana Voldsgaard, Rasmussen, Peter Vestergaard, Svendsen, Kristina Bacher, Barzinji, Ismael, Nielsen, Helle Hvilsted, Sejbæk, Tobias, Prakash, Sivagini, Stilund, Morten Leif Munding, Weglewski, Arkadiusz, Issa, Nadia Mubder, Kant, Matthias, Sellebjerg, Finn, Gray, Orla, Magyari, Melinda, Kalincik, Tomas, Cabrera-Gomez, Jose Antonio, Roullet, Etienne, Zwanikken, Cees, Den braber-Moerland, Leontien, Barnett, Michael, Hodgkinson, Suzanne, Garber, Justin, Slee, Mark, McCombe, Pamela, Taylor, Bruce, MacDonell, Richard, Massey, Jennifer, Van Pesch, Vincent, Decoo, Danny, Willekens, Barbara, Fragoso, Yara, Prevost, Julie, Prat, Alexandre, Girard, Marc, Larochelle, Catherine, Oh, Jiwon, Lalive, Patrice, Gobbi, Claudio, Horakova, Dana, Havrdova, Eva, Ampapa, Radek, Izquierdo, Guillermo, Eichau, Sara, Sanchez-Menoyo, Jose L., Ramo-Tello, Cristina, Blanco, Yolanda, Saiz, Albert, Besora, Sarah, Shaygannejad, Vahid, Cartechini, Elisabetta, Diamanti, Matteo, Amato, Maria Pia, Spitaleri, Daniele, Patti, Francesco, Chisari, Clara, D'Amico, Emanuele, Salvatore, Lo Fermo, Yamout, Bassem, Khoury, Samia J., Al-Asmi, Abdullah, Jose Sa, Maria, Al-Harbi, Talal, Karabudak, Rana, Turkoglu, Recai, Kilpatrick, Trevor, King, John, Nguyen, Ai-Lan, Dwyer, Chris, Monif, Mastura, Taylor, Lisa, Baker, Josephine, MSBase Study GroupDanish MS Registry Study Group, missing

المصدر: JAMA NEUROLOGY ; ISSN: 2168-6149 ; ISSN: 2168-6157

مصطلحات موضوعية: Medicine and Health Sciences, Neurology (clinical)

الوصف: IMPORTANCE Ocrelizumab, a humanized monoclonal antibody targeted against CD20+ B cells, reduces the frequency of relapses by 46% and disability worsening by 40% compared with interferon beta 1a in relapsing-remitting multiple sclerosis (MS). Rituximab, a chimeric monoclonal anti-CD20 agent, is often prescribed as an off-label alternative to ocrelizumab. OBJECTIVE To evaluate whether the effectiveness of rituximab is noninferior to ocrelizumab in relapsing-remitting MS. DESIGN, SETTING, AND PARTICIPANTS This was an observational cohort study conducted between January 2015 and March 2021. Patients were included in the treatment group for the duration of study therapy and were recruited from the MSBase registry and Danish MS Registry (DMSR). Included patients had a history of relapsing-remitting MS treated with ocrelizumab or rituximab, a minimum 6 months of follow-up, and sufficient data to calculate the propensity score. Patients with comparable baseline characteristics were 1:6 matched with propensity score on age, sex, MS duration, disability (Expanded Disability Status Scale), prior relapse rate, prior therapy, disease activity (relapses, disability accumulation, or both), magnetic resonance imaging lesion burden (missing values imputed), and country. EXPOSURE Treatment with ocrelizumab or rituximab after 2015. MAIN OUTCOMES AND MEASURES Noninferiority comparison of annualized rate of relapses (ARRs), with a prespecified noninferiority margin of 1.63 rate ratio. Secondary end points were relapse and 6-month confirmed disability accumulation in pairwise-censored groups. RESULTS Of the 6027 patients with MS who were treated with ocrelizumab or rituximab, a total of 1613 (mean [SD] age; 42.0 [10.8] years; 1089 female [68%]) fulfilled the inclusion criteria and were included in the analysis (898 MSBase, 715 DMSR). A total of 710 patients treated with ocrelizumab (414 MSBase, 296 DMSR) were matched with 186 patients treated with rituximab (110 MSBase, 76 DMSR). Over a pairwise censored mean (SD) follow-up of 1.4 ...

وصف الملف: application/pdf

العلاقة: https://biblio.ugent.be/publication/01H3V7X4ZJC9NSDGKQ4YZ8KWSSTest; http://hdl.handle.net/1854/LU-01H3V7X4ZJC9NSDGKQ4YZ8KWSSTest; http://doi.org/10.1001/jamaneurol.2023.1625Test; https://biblio.ugent.be/publication/01H3V7X4ZJC9NSDGKQ4YZ8KWSS/file/01H3V85T18SG00E3996891NRJXTest

الإتاحة: https://doi.org/10.1001/jamaneurol.2023.1625Test
https://biblio.ugent.be/publication/01H3V7X4ZJC9NSDGKQ4YZ8KWSSTest
http://hdl.handle.net/1854/LU-01H3V7X4ZJC9NSDGKQ4YZ8KWSSTest
https://biblio.ugent.be/publication/01H3V7X4ZJC9NSDGKQ4YZ8KWSS/file/01H3V85T18SG00E3996891NRJXTest